Follow us on:

Cizzle Biotechnology programme with US firm Bio-Techne takes major step forward (VIDEO)

Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to the completion of its Evaluation Programme with Bio-Techne for Cizzle’s CIZ1B cancer biomarker.

Allan reminds us of what the CIZ1B biomarker is, how this helps with the detection of early-stage lung cancer, why is Bio-Techne a good fit for Cizzle, how Cizzle intends to build on this relationship with Bio-Techne and bring its diagnostic solution to market and how Allan sees the outlook for the company.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

You might also enjoy reading Cizzle Biotechnology repotrs interim results and key partnerships for lung cancer detection

Find more news, interviews, share price & company profile here for:

Share this interview

Other Interviews

Cizzle Biotechnology Expanding into USA and Transforming Cancer Screening (VIDEO) October 22, 2024
Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) September 10, 2024
Cizzle Biotechnology USA and Canada Agreement Major Milestone (VIDEO) April 4, 2024
Cizzle Biotechnology to Raise £0.62m for Scale Up of Key Antibodies and Reagents (VIDEO) March 26, 2024
Cizzle Biotechnology to offer early lung cancer tech throughout the USA (VIDEO) May 9, 2022
Cizzle Biotechnology AZD 1656 deal means near term revenue streams (Interview) February 15, 2022
Cizzle Biotechnology to take early lung cancer test to £3b China market (Interview) February 4, 2022
Cizzle Biotechnology collaboration with FairJourney Biologics (Interview) July 26, 2021
Cizzle Biotechnology MOU to take diagnostic capabilities into the therapeutic arena (Interview) June 23, 2021
Cizzle Biotechnology never a better time to invest in diagnostics (Interview) May 17, 2021

More News

Cizzle Biotechnology signs exclusive licensing and partnership agreement for North America October 21, 2024
Cizzle Biotechnology repotrs interim results and key partnerships for lung cancer detection September 30, 2024
Cizzle Biotechnology collaborates with Moffitt Cancer Center September 9, 2024
Cizzle Biotechnology updates on planned strategic and exclusive licensing partner in the USA July 25, 2024
Cizzle Biotechnology accelerating growth with BBI Solutions strategic agreement July 18, 2024
Cizzle Biotechnology CIZ1B biomarker selected as part of major study with leading US cancer centre June 17, 2024
Cizzle Biotechnology publishes final results for the year ended 31 December 2023 April 30, 2024
Cizzle Biotechnology signs Exclusive Licensing Agreement for lung cancer biomarker test April 2, 2024
Cizzle Biotechnology to Raise £0.62m for Scale Up of Key Antibodies and Reagents (VIDEO) March 26, 2024
Cizzle Biotechnology Holdings Shareholder Approval for Conduit-Murphy Merger and NASDAQ Listing September 21, 2023

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.